Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2024 07:00 ET | Source: BioCardia, Inc.

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

SUNNYVALE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
August 29, 2024 08:30 ET | Source: BioCardia, Inc.

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

SUNNYVALE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
July 30, 2024 07:00 ET | Source: BioCardia, Inc.

BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family

BioCardia, Inc., today reported it has submitted a 510(k) for approval of its patented Morph® DNA™ Steerable Introducer Sheath with the FDA.
July 17, 2024 07:00 ET | Source: BioCardia, Inc.

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
January 03, 2024 07:00 ET | Source: BioCardia, Inc.

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

SUNNYVALE, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
October 12, 2021 08:00 ET | Source: BioCardia, Inc.

BioCardia Issued New U.S. Patent for Technology that Enhances Control for Interventional Catheter Based Therapies

SAN CARLOS, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and...